Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Tandem Diabetes Care (TNDM) R&D In Process (2022 - 2025)

Tandem Diabetes Care filings provide 3 years of R&D In Process readings, the most recent being $75.2 million for Q1 2025.

  • On a quarterly basis, R&D In Process changed N/A to $75.2 million in Q1 2025 year-over-year; TTM through Dec 2025 was $75.2 million, a N/A change, with the full-year FY2025 number at $75.2 million, changed N/A from a year prior.
  • R&D In Process hit $75.2 million in Q1 2025 for Tandem Diabetes Care, down from $78.8 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $78.8 million in Q1 2023 to a low of $23000.0 in Q4 2022.
  • Median R&D In Process over the past 3 years was $53.1 million (2022), compared with a mean of $46.2 million.